Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells

PURPOSE: The potential of members of the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) has not been extensively addressed. Although phase III clinical trials showed no survival benefits of erlotinib in patients with advanced CCA, the outcome of the standa...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Res Treat
Main Authors: Boonsri, Boonyakorn, Yacqub-Usman, Kiren, Thintharua, Pakpoom, Myint, Kyaw Zwar, Sae-Lao, Thannicha, Collier, Pam, Suriyonplengsaeng, Chinnawut, Larbcharoensub, Noppadol, Balasubramanian, Brinda, Venkatraman, Simran, Egbuniwe, Isioma U., Gomez, Dhanwant, Mukherjee, Abhik, Kumkate, Supeecha, Janvilisri, Tavan, Zaitoun, Abed M, Kuakpaetoon, Thiti, Tohtong, Rutaiwan, Grabowska, Anna M, Bates, David O., Wongprasert, Kanokpan
פורמט: Artigo
שפה:Inglês
יצא לאור: Korean Cancer Association 2021
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053863/
https://ncbi.nlm.nih.gov/pubmed/33070556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2020.585
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים